Taro Q1 FY18(Sun Pharma subsidiary)

1. Net profit down 50% at USD 54.5 million v/s USD 109.9 million (YoY)
2. Net sales down 31% at USD 161.3 million v/s 233.8 million (YoY)
3. Operating income down 45% at USD 77.6 million v/s USD 142.6 million (YoY)
4. Operating margin at 48.1 % v/s 61% (YoY)